Paxlovid (nirmatrelvir-ritonavir) is efficient at stopping hospitalization and demise from COVID-19, however few folks use it. A paper by SteelFisher et al. (2024) surveyed 1,430 American adults to search out out why. Their survey revealed sufferers had a lack of information of the therapy in addition to misinformation concerning the therapy (amongst those that had been conscious of it). Particularly:
A majority of respondents (85 p.c) had no or low consciousness of Paxlovid, together with 31 p.c who had by no means heard of it. Even amongst those that had been conscious of the drug, many held misperceptions about its effectiveness (39 p.c), antagonistic results (86 p.c), and requisite timing (61 p.c) that would result in underuse. Decrease consciousness and misperceptions had been extra widespread amongst medically weak and deprived populations who would possibly profit most from Paxlovid entry, together with adults unvaccinated towards COVID-19, these with decrease ranges of training, and Black and Hispanic or Latino adults.
You’ll be able to learn the total paper right here.